English (United Kingdom)French (Fr)
Home Wellness Articles Informed Choice Pediarix 5 in 1 Vaccine

Pediarix 5 in 1 Vaccine

Written by Pathways Magazine   
Tuesday, 01 March 2005 00:00

In December 2002, the FDA approved a new combination vaccine for use in children under 6 months of age. GlaxoSmithKline’s Pediarix is for diphtheria, tetanus, whooping cough, hepatitis B, and polio.

Dr. Sherri Tenpenny, D.O., a nationally renowned and respected vaccine expert, criticized the studies that led to Pediarix's FDA approval.

The study claimed that “there were no vaccine-related serious adverse events to any group after any vaccine dose,” but serious adverse events did occur.

Quoting the study, Dr. Tenpenny writes: “Two subjects withdrew from the study because of serious adverse events that were determined by the safety monitor to be unrelated to vaccination. One subject in Group A was diagnosed with a seizure disorder 14 days after the first immunization. Another subject in Group B had a neuroblastoma detected 6 weeks after the first immunization. Six other reported serious adverse events involved hospitalizations for brochiolitis/pneumonia (4), meningitis (1) and apnea (1) and were also determined to be unrelated to vaccination.

“Why is it,” she asks, "that whenever an adverse event occurs during the course of a vaccine clinical trial, that ‘event’ is never related to vaccination?”

Dr. Tenpenny urges consumers to read the package inserts for vaccines with care, especially the one for Pediarix. Pediarix contains a troubling list of additives, adjuvants and contaminants including formaldehyde, glutaraldehyde, 2-Phenoxyethanol (antifreeze), Thimerosal (12.5 nanograms), VERO (monkey) cells, neomycin, polymyxin B, polysorbate 80, and yeast protein.

Neergaard, Lauran. New vaccine to cut 6 of 20 shots for babies. The Herald-Sun, 17 December 2002.

Tenpenny, Sherri, D.O. Commentary on Pediarix. January 25, 2003. www.mercola.com.

Pathways Issue 5 CoverThis article appeared in Pathways to Family Wellness magazine, Issue #05.

To purchase this issue, Order Here.